Enabling allogeneic therapies: CIRM-funded strategies for immune tolerance and immune evasion.
Ontology highlight
ABSTRACT: A major goal for the field of regenerative medicine is to enable the safe and durable engraftment of allogeneic tissues and organs. In contrast to autologous therapies, allogeneic therapies can be produced for many patients, thus reducing costs and increasing availability. However, the need to overcome strong immune system barriers to engraftment poses a significant biological challenge to widespread adoption of allogeneic therapies. While the use of powerful immunosuppressant drugs has enabled the engraftment of lifesaving organ transplants, these drugs have serious side effects and often the organ is eventually rejected by the recipient immune system. Two conceptually different strategies have emerged to enable durable engraftment of allogeneic therapies in the absence of immune suppress
SUBMITTER: Kadyk LC
PROVIDER: S-EPMC7445020 | biostudies-literature | 2020 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA